MedTrace Logo

Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

NCT00595309 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2014-05-16

Study results available
· View outcomes & findings →

Summary

The objective is to assess the effect of a booster vaccination on immunogenicity of IC51 in terms of seroconversion rate.

Conditions

  • Japanese Encephalitis

Interventions

BIOLOGICAL

IC51

IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization

Sponsors & Collaborators

  • Valneva Austria GmbH

    lead INDUSTRY

Principal Investigators

  • Susanne Eder · Valneva Austria GmbH

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595309 on ClinicalTrials.gov